查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017218

血液培養檢測市場：2026-2032年全球市場預測（依產品類型、技術、檢測類型、檢體類型、實施方法、最終用戶和應用分類）

Blood Culture Test Market by Product, Technology, Test Type, Sample Type, Mode, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年血液培養檢測市場價值為56.7億美元，預計到2026年將成長至60.3億美元，複合年成長率為7.19%，到2032年將達到92.3億美元。

主要市場統計數據
基準年 2025 56.7億美元
預計年份：2026年 60.3億美元
預測年份 2032 92.3億美元
複合年成長率 (%) 7.19%

簡要概述血液培養診斷在現代醫療保健服務體系中不斷發展的臨床和運作重要性。

血液培養檢測仍是診斷血流感染疾病和指南抗生素治療的基本診斷程序。儘管培養系統、自動化和分子輔助技術的進步提高了血液培養工作流程的臨床效用和操作效率，但檢查室仍在不斷努力平衡檢體處理的速度、敏感度和成本。在臨床實踐中，及時檢測能夠直接影響患者預後，因為它有助於標靶治療方案並減少不必要的抗生素暴露，因此血液培養能力是急診過程中不可或缺的一部分。

創新、自動化、供應鏈韌性和診斷管理如何共同改變血液培養檢測中的檢查室工作流程和臨床路徑。

受技術創新、工作流程最佳化以及檢查室在診療路徑中角色重新定義的推動，血液感染疾病的診斷方法正在經歷一場變革。儘管傳統的培養技術仍然能夠提供重要的表現型信息，但分子診斷平台和快速鑑定方法正在拓展臨床醫生的工具箱，使他們能夠更早地減少經驗性治療，並提高抗生素的合理使用。技術的多元化促使檢查室重新思考其檢測流程，並採用能夠互補地利用培養和分子診斷優勢的混合方法。

評估關稅對血液培養診斷領域的成本結構、採購決策和分銷模式造成的採購挑戰和供應鏈策略影響。

近期關稅趨勢和貿易政策調整對參與血液培養診斷的臨床檢查室、製造商和經銷商產生了顯著的下游影響。某些檢測設備和耗材進口關稅的提高可能會增加接收成本，迫使採購團隊重新評估其供應商組合，並協商長期合約以穩定價格。為此，製造商可能會考慮透過地理多元化生產、替代籌資策略或調整產品組合來降低關稅風險，同時維持其利潤結構。

綜合細分分析，概述產品、最終用戶、技術、測試類型、應用、檢體類型和實施方法對產品採用和採購趨勢的影響。

對各類產品類型的詳細分析揭示了耗材和儀器的具體考慮因素，這些因素會影響產品的採用和採購決策。耗材，包括試管、培養基和試劑組，是持續營運成本的組成部分，需要評估其批次間一致性、儲存需求以及與自動化系統的兼容性。儀器，例如分析儀器和自動化系統，則需要進行資本規劃、與實驗室資訊系統 (LIS) 整合以及簽訂長期服務合約。因此，採購決策通常圖在耗材供應的可預測性與引入分析儀器所帶來的效率提升和驗證負擔之間取得平衡。

影響美洲、歐洲、中東和非洲以及亞太地區技術採用、採購偏好和服務模式的區域趨勢和基礎設施因素。

地理趨勢導致美洲、歐洲、中東和非洲以及亞太地區的需求促進因素和營運限制各不相同，這反映了各地區獨特的醫療基礎設施、報銷模式和區域供應鏈結構。在美洲，大規模的綜合醫療體系和對診斷管理的重視促使人們傾向於高通量自動化和互聯互通，而獨立實驗室則推動了分散式服務模式的發展。在歐洲、中東和非洲，監管協調、多樣化的採購框架和基礎設施的異質性並存，這為能夠應對不同臨床環境的模組化解決方案創造了機會。在亞太地區，快速發展的實驗室網路與成熟的高效中心並存，使得人們對可擴展的自動化和分子診斷支援技術產生了濃厚的興趣，以應對地方性感染和院內感染的挑戰。

競爭優勢源自於一體化的解決方案組合、強大的服務網路以及與檢查室工作流程和臨床重點一致的有針對性的創新。

在血液培養檢測生態系統中，產品可靠性、整合能力和服務卓越性是企業獲得競爭優勢的關鍵。擁有從耗材到儀器等廣泛產品組合的領導企業，能夠提供端到端的解決方案，從而降低供應商管理的複雜性，並建立無縫的工作流程，進而獲得競爭優勢。那些投資於互通性、數據整合和以用戶為中心的設計，以最大限度地減少人工操作時間並簡化結果報告流程的企業，能夠增強其對高通量檢查室和醫院系統的價值提案。同時，專注於快速分子鑑定和高靈敏度檢測等細分技術領域的專業公司，可以在將先進診斷視為優先事項的參考中心和三級醫療機構中佔據戰略地位。

為供應商和檢查室管理人員提供可操作的策略重點，以提高診斷價值、營運彈性和以合作夥伴為中心的商業化模式。

產業領導者若想鞏固市場地位並提升臨床影響力，應圍繞兩大目標進行投資：提高診斷價值和增強營運韌性。首先，應優先考慮能夠連接表現型培養和快速分子鑑定的解決方案，以便在現有檢測流程的限制下提供臨床可用的結果。這使得機構能夠在滿足下游流程中表現型藥敏試驗需求的同時，及時向臨床醫師提供資訊。其次，應投資於自動化和資訊技術，以減少人為操作差異並縮短檢測結果報告時間，並確保建立完善的培訓和檢驗機制，從而確保這些技術的成功應用。

採用嚴謹的混合方法研究途徑，結合對從業者的訪談、技術文獻和檢驗程序，得出可操作和可重複的診斷見解。

本研究採用混合方法，整合了與血液培養診斷相關的臨床、商業性和營運方面的見解。主要資訊來源包括對實驗室管理人員、採購負責人和臨床微生物學家的結構化訪談，以深入了解工作流程的限制、檢驗實踐和臨床應用案例。二級資訊來源包括同行評審文獻、監管指南和製造商技術文檔，以確保符合現行標準和性能要求。分析結合了定性主題整合和跨產品類型、最終用戶、技術和地區的橫斷面比較，以識別一致的模式和差異化因素。

整合臨床、營運和策略要求，指導血液培養診斷解決方案的有效實施和永續部署。

血液培養診斷正處於變革的關鍵時期，隨著技術創新、供應鏈考量和臨床需求的融合，檢查室的運作方式正在重塑。儘管傳統的培養系統仍然是表現型藥敏試驗的核心，但分子診斷和自動化輔助技術正在重新定義人們對速度和診斷準確性的期望。這些互補的方法為混合診斷路徑創造了機遇，從而在快速鑑定和全面藥敏評估之間取得平衡，進而改善藥物使用和患者預後。在營運方面，檢查室在實施新平台時必須應對價格調整、供應鏈波動以及整合和檢驗要求帶來的成本壓力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血液培養檢測市場：依產品分類

  • 消耗品
    • 瓶子
    • 培養基
    • 試劑組
  • 裝置
    • 分析器
    • 自動化系統

第9章 血液培養檢測市場：依技術分類

  • 傳統的
  • 分子
    • 次世代定序
    • 聚合酵素鏈鎖反應

第10章 血液培養檢測市場（依檢測類型分類）

  • 自動的
  • 手動的

第11章 依檢體類型分類的血液培養檢測市場

  • 電漿
  • 全血

第12章 依實施方式分類的血液培養檢測市場

  • 中心檢查室
  • 照護端
    • 床頭
    • 攜帶式的

第13章 血液培養檢測市場：依最終用戶分類

  • 門診部
    • 獨立診所
    • 私人診所
  • 血庫
  • 診斷檢查室
    • 醫院檢查室
    • 獨立檢測實驗室
  • 醫院和診所
    • 二級醫院
    • 三級醫療機構

第14章 血液培養檢測市場：依應用領域分類

  • 細菌
    • 革蘭氏陰性菌
    • 革蘭氏陽性菌
  • 真菌
    • 絲狀真菌
    • 酵母菌
  • 分枝桿菌

第15章 血液培養檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 血液培養檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 血液培養檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國血液培養檢測市場

第19章：中國血液培養檢測市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accelerate Diagnostics, Inc.
  • Autobio Diagnostics Co. Ltd.
  • Becton Dickinson and Company
  • bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche
  • Siemens Healthineers AG
  • Sigma-Aldrich
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-035DA3C63737

The Blood Culture Test Market was valued at USD 5.67 billion in 2025 and is projected to grow to USD 6.03 billion in 2026, with a CAGR of 7.19%, reaching USD 9.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.67 billion
Estimated Year [2026] USD 6.03 billion
Forecast Year [2032] USD 9.23 billion
CAGR (%) 7.19%

A concise orientation to the evolving clinical and operational significance of blood culture diagnostics within modern healthcare delivery systems

Blood culture testing remains a foundational diagnostic procedure for detecting bloodstream infections and guiding antimicrobial therapy. Advances in culture systems, automation, and molecular adjuncts have increased the clinical relevance and operational throughput of blood culture workflows, while laboratories continually balance speed, sensitivity, and cost in specimen processing. In clinical settings, timely detection directly influences patient outcomes by informing targeted therapy and reducing inappropriate antimicrobial exposure, making blood culture capability a critical component of acute care pathways.

In parallel, laboratory managers and procurement specialists must navigate a landscape shaped by technology convergence, supply chain dynamics, and evolving regulatory expectations. The integration of automated analyzers with front-end specimen handling and data connectivity has improved consistency and reduced hands-on time, yet it has also introduced new vendor interoperability and validation considerations. As healthcare systems prioritize diagnostic stewardship and laboratory efficiency, blood culture testing is experiencing both operational refinement and strategic reassessment across hospital systems, independent laboratories, and outpatient facilities.

This executive summary synthesizes current dynamics affecting clinical practice, technology adoption, and organizational investment decisions. It highlights how shifts in diagnostic paradigms, policy environments, and end-user requirements are reshaping procurement preferences and implementation strategies, with implications for clinical laboratories, device manufacturers, and healthcare administrators seeking to optimize diagnostic value across care continuums.

How innovation, automation, supply chain resilience, and diagnostic stewardship are jointly reshaping laboratory workflows and clinical pathways in blood culture testing

The diagnostic landscape for bloodstream infection detection is undergoing transformative shifts driven by technological innovation, workflow optimization, and a reimagining of laboratory roles within care pathways. Conventional culture techniques continue to provide essential phenotypic information, yet molecular platforms and rapid identification methods have expanded the clinician's toolkit, enabling earlier de-escalation of empiric therapy and enhanced antimicrobial stewardship. This technological diversification has prompted laboratories to re-evaluate test algorithms and to adopt hybrid approaches that leverage both culture and molecular modalities for complementary strengths.

Operationally, increased adoption of automation across pre-analytical and analytical stages is altering laboratory staffing models and throughput expectations. Automation reduces manual variability and supports higher sample volumes, but it also necessitates investments in training, validation, and informatics to ensure seamless integration. At the same time, supply chain resilience has emerged as a strategic priority. Laboratories and suppliers are exploring redundancy in sourcing consumables and diversifying logistics to mitigate disruptions, which in turn affects procurement cycles and inventory management practices.

Clinically, there is an intensified focus on diagnostic stewardship, driven by payer scrutiny and institutional quality initiatives. Diagnostic pathways are being redesigned to emphasize timely and accurate detection while avoiding unnecessary testing. This shift influences adoption patterns for both automated and manual testing modalities and underscores the importance of actionable reporting, result turnaround time, and linkage to clinical decision support systems. Taken together, these trends are not only reshaping laboratory operations but also creating new opportunities for vendors and health systems to collaborate on integrated solutions that deliver measurable clinical and economic value.

Assessment of tariff-driven procurement stressors and supply chain strategies that are influencing cost structures, sourcing decisions, and distribution models across blood culture diagnostics

Recent tariff developments and trade policy adjustments have created material downstream effects for clinical laboratories, manufacturers, and distributors involved in blood culture diagnostics. Increased import duties on certain laboratory equipment and consumables can raise landed costs, prompting procurement teams to reassess supplier portfolios and negotiate longer-term contracts to stabilize pricing. In response, manufacturers may explore regionalization of production, alternative sourcing strategies, or changes to product configurations to mitigate tariff exposure while preserving margin structures.

These dynamics influence procurement behavior across end users, with hospitals and independent laboratories weighing the trade-offs between unit cost, reliability of supply, and vendor support commitments. Some organizations may prioritize stocking larger inventories of critical consumables to buffer against price volatility, while others will seek service models that reduce capital expenditure and transfer supply risk to vendors through managed services or reagent-rental agreements. Moreover, increased costs can accelerate interest in automation and workflow efficiency initiatives as organizations seek to offset higher per-unit prices through labor savings and reduced waste.

At the same time, regulatory and customs complexities associated with tariff implementation can extend lead times and complicate product launch strategies for new analyzers and consumables. Manufacturers and distributors are therefore adapting distribution and logistics frameworks, enhancing visibility across supply chains, and collaborating with customers to develop contingency plans. Collectively, these changes encourage more strategic procurement planning, foster supplier diversification, and create incentives for supply chain transparency and regional manufacturing investment to reduce the cumulative impact of tariff-related cost pressures.

Integrated segmentation analysis outlining product, end-user, technological, test-type, application, sample type, and mode implications that shape adoption and procurement dynamics

A granular view across product categories reveals distinct considerations for consumables and instruments that shape adoption and purchasing behavior. Consumables, encompassing bottles, culture media, and reagent kits, drive recurring operating cost and are evaluated for lot-to-lot consistency, storage requirements, and compatibility with automated systems. Instruments, including analyzers and automation systems, require capital planning, integration with laboratory information systems, and long-term service agreements. Consequently, buying decisions often balance the predictability of consumable supply against the efficiency gains and validation burden associated with analyzer deployment.

End-user segmentation highlights that ambulatory care centers, blood banks, diagnostic laboratories, and hospitals and clinics each follow different operational models and procurement imperatives. Ambulatory care delivery is typically split between independent clinics and physician offices, which prioritize ease of use and compact footprint. Blood banks emphasize reliability and regulatory compliance, whereas diagnostic laboratories - including hospital-based labs and independent labs - focus on throughput, turnaround time, and interoperability. Secondary and tertiary hospitals within the hospital and clinic segment demand scalable solutions, with tertiary centers often integrating advanced identification technologies.

Technology choices between conventional and molecular methods determine diagnostic pathways. Conventional culture remains essential for susceptibility testing and phenotypic confirmation, while molecular approaches, such as next generation sequencing and polymerase chain reaction, are increasingly used for rapid identification and characterization in complex cases. Test type preferences between automated and manual workflows reflect institutional priorities: automated platforms favor consistency and reduced hands-on time, whereas manual testing may persist in low-volume or resource-constrained settings. Application-specific requirements further differentiate use cases, with bacterial testing divided into gram-negative and gram-positive targets, fungal testing addressing filamentous fungi and yeast, and mycobacterial assays requiring specialized processing. Sample type considerations between plasma and whole blood influence processing protocols and instrument compatibility, and mode of delivery, whether central laboratory or point of care, including bedside and portable options, drives decisions about decentralization versus consolidated testing capacity. Together, these segmentation lenses provide a multidimensional framework for aligning product development, commercialization, and clinical implementation strategies.

Regional dynamics and infrastructure factors that steer technology adoption, procurement preferences, and service models across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Geographic dynamics create differentiated demand drivers and operational constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions, each reflecting unique healthcare infrastructure, reimbursement models, and regional supply chain architectures. In the Americas, large integrated healthcare systems and a focus on diagnostic stewardship influence preferences for high-throughput automation and connectivity, while independent laboratories drive decentralized service provision. Within Europe, Middle East & Africa, regulatory harmonization efforts coexist with varied purchasing frameworks and infrastructure heterogeneity, creating opportunities for modular solutions that accommodate diverse clinical settings. The Asia-Pacific region presents a mix of rapidly developing laboratory networks alongside mature centers of excellence, with considerable interest in scalable automation and molecular adjuncts to address both endemic and hospital-acquired infection challenges.

Regional procurement strategies differ in how they balance capital investment with operational expenditures. In well-capitalized systems, there is often appetite for advanced analyzers and integrated automation to support high-volume workflows, whereas in regions with resource constraints, manual or semi-automated approaches and durable consumables retain relevance. Cross-border logistics and tariff regimes further shape distribution strategies, prompting vendors and health systems to consider regional warehousing, local partnerships, and flexible service models to maintain supply reliability. Importantly, clinical priorities such as antimicrobial resistance surveillance, sepsis management programs, and public health reporting influence uptake of specific technologies and assays, leading to regionally tailored product roadmaps and support services that align with local clinical imperatives.

Competitive differentiation emerges from integrated solution portfolios, robust service networks, and targeted innovations that align with laboratory workflows and clinical priorities

Competitive positioning in the blood culture testing ecosystem is shaped by companies that excel in product reliability, integration capabilities, and service excellence. Leaders with broad portfolios across consumables and instrumentation gain advantage by offering end-to-end solutions that reduce the complexity of supplier management and validate seamless workflows. Organizations that invest in interoperability, data integration, and user-centered design to minimize hands-on time and streamline result reporting strengthen their value proposition to high-volume laboratories and hospital systems. Conversely, specialized companies that focus on niche technology areas-such as rapid molecular identification or high-sensitivity detection-can secure strategic placements within reference centers and tertiary institutions where advanced diagnostics are prioritized.

Partnership strategies and channel models also differentiate competitive approaches. Firms that cultivate robust distributor networks and local technical support are better positioned to serve diverse geographies, while those that offer embedded service programs, reagent-rental options, or outcome-linked contracting can alleviate capital constraints for customers. Additionally, companies that demonstrate supply chain transparency and responsiveness during periods of disruption build trust and long-term relationships with institutional buyers. Innovation pipelines that integrate automation, molecular adjuncts, and digital reporting capabilities offer incremental clinical and operational benefits, and organizations that align R&D investments with real-world laboratory workflows will likely secure preferential consideration in procurement decisions.

Ultimately, company success is increasingly tied to the ability to deliver demonstrable operational efficiencies, regulatory-compliant performance, and scalable support models that align with the clinical and financial objectives of diverse laboratory customers.

Actionable strategic priorities for vendors and laboratory leaders to enhance diagnostic value, operational resilience, and partner-focused commercialization models

Industry leaders seeking to strengthen market position and clinical impact should align investments with the twin objectives of improving diagnostic value and enhancing operational resilience. First, prioritize solutions that bridge phenotypic culture and rapid molecular identification to deliver clinically actionable results within the constraints of existing laboratory workflows. By doing so, organizations can support clinicians with timely information while preserving the downstream need for phenotypic susceptibility testing. Second, invest in automation and informatics that reduce manual variability and shorten turnaround times, ensuring that technology deployments are accompanied by robust training and validation programs to secure adoption.

Third, build supply chain flexibility through diversified sourcing, regional warehousing, and transparent inventory management. Such measures reduce vulnerability to tariff-induced cost shifts and logistical bottlenecks. Fourth, engage end users through outcome-focused service offerings, including reagent-rental models, managed reagent programs, and performance-based contracting that align vendor incentives with laboratory throughput and quality objectives. Fifth, pursue partnerships with clinical teams to embed diagnostic stewardship principles into testing algorithms and reporting formats, thereby strengthening the linkage between laboratory outputs and therapeutic decision-making. Finally, incorporate scalability into product design so that solutions are adaptable across ambulatory centers, blood banks, reference labs, and hospital systems, supporting phased upgrades and modular deployments that match capital cycles and clinical demand.

A rigorous mixed-methods research approach combining practitioner interviews, technical literature, and validation steps to produce actionable and reproducible diagnostic insights

This research employed a mixed-methods approach to synthesize clinical, commercial, and operational insights relevant to blood culture diagnostics. Primary inputs included structured interviews with laboratory directors, procurement officers, and clinical microbiologists, providing contextual understanding of workflow constraints, validation practices, and clinical use cases. Secondary sources comprised peer-reviewed literature, regulatory guidance, and manufacturer technical documentation to ensure alignment with current standards and performance expectations. The analysis integrated qualitative thematic synthesis with cross-sectional comparisons across product categories, end users, technologies, and geographic regions to identify consistent patterns and differentiated drivers.

To enhance reliability, findings were triangulated through multiple data streams and validated against practitioner feedback during expert review sessions. Methodological safeguards included explicit documentation of inclusion criteria for literature and technical documents, and careful delineation of technology definitions to distinguish conventional culture processes from molecular adjuncts. The approach prioritized reproducibility by outlining data sources, interview protocols, and analytic frameworks, enabling stakeholders to interrogate assumptions and adapt insights to their specific operational contexts. While this synthesis emphasizes practical implications, it remains grounded in established laboratory practice and contemporary diagnostic trends, providing a credible foundation for strategic planning and operational optimization.

Synthesis of clinical, operational, and strategic imperatives that converge to guide effective adoption and sustainable deployment of blood culture diagnostic solutions

Blood culture diagnostics are at an inflection point where technological innovation, supply chain considerations, and clinical priorities converge to reshape laboratory practice. Conventional culture systems remain central for phenotype-based susceptibility testing, while molecular and automated adjuncts are redefining expectations for speed and diagnostic resolution. These complementary modalities create opportunities for hybrid diagnostic pathways that balance rapid identification with comprehensive susceptibility determination, thereby improving stewardship and patient outcomes. Operationally, laboratories must navigate tariff-related cost pressures, supply chain variability, and the demands of integration and validation when adopting new platforms.

Strategic responses that emphasize interoperability, regional supply resilience, and outcome-focused service models will be most effective in sustaining performance and value. By aligning product portfolios with the nuanced needs of different end users - from bedside point-of-care contexts to high-throughput reference laboratories - vendors and healthcare organizations can enhance diagnostic impact while managing total cost of operation. Looking ahead, collaborative approaches that connect manufacturers, laboratory leaders, and clinical teams will accelerate the translation of technological advances into measurable clinical benefits, supporting safer, faster, and more targeted care for patients with suspected bloodstream infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Culture Test Market, by Product

  • 8.1. Consumables
    • 8.1.1. Bottles
    • 8.1.2. Culture Media
    • 8.1.3. Reagent Kits
  • 8.2. Instruments
    • 8.2.1. Analyzers
    • 8.2.2. Automation Systems

9. Blood Culture Test Market, by Technology

  • 9.1. Conventional
  • 9.2. Molecular
    • 9.2.1. Next Generation Sequencing
    • 9.2.2. Polymerase Chain Reaction

10. Blood Culture Test Market, by Test Type

  • 10.1. Automated
  • 10.2. Manual

11. Blood Culture Test Market, by Sample Type

  • 11.1. Plasma
  • 11.2. Whole Blood

12. Blood Culture Test Market, by Mode

  • 12.1. Central Lab
  • 12.2. Point Of Care
    • 12.2.1. Bedside
    • 12.2.2. Portable

13. Blood Culture Test Market, by End User

  • 13.1. Ambulatory Care Centers
    • 13.1.1. Independent Clinics
    • 13.1.2. Physician Offices
  • 13.2. Blood Banks
  • 13.3. Diagnostic Laboratories
    • 13.3.1. Hospital Based Labs
    • 13.3.2. Independent Labs
  • 13.4. Hospitals & Clinics
    • 13.4.1. Secondary Hospitals
    • 13.4.2. Tertiary Hospitals

14. Blood Culture Test Market, by Application

  • 14.1. Bacterial
    • 14.1.1. Gram Negative
    • 14.1.2. Gram Positive
  • 14.2. Fungal
    • 14.2.1. Filamentous Fungi
    • 14.2.2. Yeast
  • 14.3. Mycobacterial

15. Blood Culture Test Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Blood Culture Test Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Blood Culture Test Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Blood Culture Test Market

19. China Blood Culture Test Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Accelerate Diagnostics, Inc.
  • 20.6. Autobio Diagnostics Co. Ltd.
  • 20.7. Becton Dickinson and Company
  • 20.8. bio-Rad Laboratories, Inc.
  • 20.9. bioMerieux SA
  • 20.10. F. Hoffmann-La Roche
  • 20.11. Siemens Healthineers AG
  • 20.12. Sigma-Aldrich
  • 20.13. Sysmex Corporation
  • 20.14. Thermo Fisher Scientific Inc.
  • 20.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD CULTURE TEST MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD CULTURE TEST MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 281. GCC BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 283. GCC BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 284. GCC BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 287. GCC BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. GCC BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. GCC BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 294. GCC BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. GCC BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 297. GCC BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 332. G7 BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 333. G7 BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 334. G7 BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 335. G7 BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 336. G7 BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 337. G7 BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 338. G7 BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. G7 BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. G7 BLOOD CULTURE TEST MARKET